Hyung Tak Lee1, June Namgung2, Young-Hyo Lim3, Hwan-Cheol Park3, Jin-Kyu Park3, Jinho Shin3. 1. Departments of Internal Medicine, Gumdan Top General Hospital, Incheon, Republic of Korea. 2. 2Division of Cardiology, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Republic of Korea. 3. 3Division of Cardiology, Departments of Internal Medicine, Hanyang University, College of Medicine, 222 Wangsimni-ro Sungdong-gu, 133-792 Seoul, Republic of Korea.
Abstract
BACKGROUND: Previous studies demonstrated that visit-to-visit variability of blood pressure (BP) has significant relationship with cardiovascular disease. Visit-to-visit variability in BP might have prognostic value for cardiovascular disease. The aim of this study is to evaluate the effect of visit-to-visit variability in BP on development of metabolic syndrome in general population without cardiovascular disease, diabetes mellitus, metabolic syndrome, and BP medication. METHOD: We used data from the Korean Genome Epidemiology Study conducted by the Korean Centers for Disease Control and Prevention. All cohorts who were followed first 3 periods formed the basis of the study sample, which consisted of 7195 people. Of these samples, 3431 subjects who had cardiovascular disease, diabetes mellitus, or metabolic syndrome were excluded, and 312 subjects who were using antihypertensive medication in first 3 periods were excluded. Our final study sample consisted of 3452 cohorts. RESULTS: The mean age was 53.5 (8.25) years. The proportion of male was 50.2%. Average follow-up duration was 5.91 (0.17) years. In generalized estimating equation, the development of metabolic syndrome was associated with mean systolic BP (SBP) (Odd ratio (OR) 1.042, 95% confidence interval (CI) 1.035-1.048, p < 0.001), mean diastolic BP (DBP) (OR 1.058, 95% CI 1.049-1.069, p < 0.001), standard deviation (SD) of SBP (OR 1.036, 95% CI 1.017-1.055, p < 0.001), SD of DBP (OR 1.053, 95% CI 1.027-1.080, p < 0.001), and coefficient of variation (CV) of DBP (OR 1.025, 95% CI 1.005-1.046, p = 0.016) after adjusted for age, sex, and metabolic syndrome component. When mean SBP, mean DBP, SBP variability, and DBP variability were entered all together in the analysis model, SD of DBP (OR 1.033, 95% CI 1.003-1.063, p = 0.030) and CV of DBP (OR 1.027, 95% CI 1.004-1.051, p = 0.020) were significantly associated with the development of metabolic syndrome. CONCLUSION: In general population without cardiovascular disease, diabetes mellitus, metabolic syndrome, and BP medication, SD of DBP and CV of DBP was associated with the development of metabolic syndrome. Visit-to-visit variability in DBP might be helpful for the prediction of future metabolic syndrome development.
BACKGROUND: Previous studies demonstrated that visit-to-visit variability of blood pressure (BP) has significant relationship with cardiovascular disease. Visit-to-visit variability in BP might have prognostic value for cardiovascular disease. The aim of this study is to evaluate the effect of visit-to-visit variability in BP on development of metabolic syndrome in general population without cardiovascular disease, diabetes mellitus, metabolic syndrome, and BP medication. METHOD: We used data from the Korean Genome Epidemiology Study conducted by the Korean Centers for Disease Control and Prevention. All cohorts who were followed first 3 periods formed the basis of the study sample, which consisted of 7195 people. Of these samples, 3431 subjects who had cardiovascular disease, diabetes mellitus, or metabolic syndrome were excluded, and 312 subjects who were using antihypertensive medication in first 3 periods were excluded. Our final study sample consisted of 3452 cohorts. RESULTS: The mean age was 53.5 (8.25) years. The proportion of male was 50.2%. Average follow-up duration was 5.91 (0.17) years. In generalized estimating equation, the development of metabolic syndrome was associated with mean systolic BP (SBP) (Odd ratio (OR) 1.042, 95% confidence interval (CI) 1.035-1.048, p < 0.001), mean diastolic BP (DBP) (OR 1.058, 95% CI 1.049-1.069, p < 0.001), standard deviation (SD) of SBP (OR 1.036, 95% CI 1.017-1.055, p < 0.001), SD of DBP (OR 1.053, 95% CI 1.027-1.080, p < 0.001), and coefficient of variation (CV) of DBP (OR 1.025, 95% CI 1.005-1.046, p = 0.016) after adjusted for age, sex, and metabolic syndrome component. When mean SBP, mean DBP, SBP variability, and DBP variability were entered all together in the analysis model, SD of DBP (OR 1.033, 95% CI 1.003-1.063, p = 0.030) and CV of DBP (OR 1.027, 95% CI 1.004-1.051, p = 0.020) were significantly associated with the development of metabolic syndrome. CONCLUSION: In general population without cardiovascular disease, diabetes mellitus, metabolic syndrome, and BP medication, SD of DBP and CV of DBP was associated with the development of metabolic syndrome. Visit-to-visit variability in DBP might be helpful for the prediction of future metabolic syndrome development.
Authors: Elaine M Urbina; Thomas R Kimball; Philip R Khoury; Stephen R Daniels; Lawrence M Dolan Journal: J Hypertens Date: 2010-08 Impact factor: 4.844
Authors: Stanley S Franklin; Jose R Pio; Nathan D Wong; Martin G Larson; Eric P Leip; Ramachandran S Vasan; Daniel Levy Journal: Circulation Date: 2005-02-21 Impact factor: 29.690
Authors: Scott M Grundy; James I Cleeman; Stephen R Daniels; Karen A Donato; Robert H Eckel; Barry A Franklin; David J Gordon; Ronald M Krauss; Peter J Savage; Sidney C Smith; John A Spertus; Fernando Costa Journal: Circulation Date: 2005-09-12 Impact factor: 29.690
Authors: Apoor S Gami; Brandi J Witt; Daniel E Howard; Patricia J Erwin; Lisa A Gami; Virend K Somers; Victor M Montori Journal: J Am Coll Cardiol Date: 2007-01-12 Impact factor: 24.094
Authors: Salvatore Mottillo; Kristian B Filion; Jacques Genest; Lawrence Joseph; Louise Pilote; Paul Poirier; Stéphane Rinfret; Ernesto L Schiffrin; Mark J Eisenberg Journal: J Am Coll Cardiol Date: 2010-09-28 Impact factor: 24.094
Authors: Peter M Rothwell; Sally C Howard; Eamon Dolan; Eoin O'Brien; Joanna E Dobson; Bjorn Dahlöf; Neil R Poulter; Peter S Sever Journal: Lancet Neurol Date: 2010-03-11 Impact factor: 44.182
Authors: Peter M Rothwell; Sally C Howard; Eamon Dolan; Eoin O'Brien; Joanna E Dobson; Bjorn Dahlöf; Peter S Sever; Neil R Poulter Journal: Lancet Date: 2010-03-13 Impact factor: 79.321